tbuckley/cabot-search huggingface dataset:
N-carboxymethyl chitosan/sodium alginate composite hydrogel loading plasmid DNA as a promising gene activated matrix for in-situ burn wound treatment
Authors: Litong Wang, Le Sun, Zhiyang Gu, Wenya Li, Lili Guo, Saibo Ma, Lan Guo, Wangwang Zhang, Baoqin Han, Jing Chang
Journal: Bioactive Materials (2021)

Improving the degree of vascularization through the regulation of wound microenvironment is crucial for wound repair. Gene activated matrix (GAM) technology provides a new approach for skin regeneration. It is a local gene delivery system that can not only maintain a moist environment, but also increase the concentration of local active factors. For this purpose, we fabricated the mVEGF165/TGF-β1 gene-loaded N-carboxymethyl chitosan/sodium alginate hydrogel and studied its effect on promoting deep second degree burn wound repair. The average diameter of the hydrogel pores was 100 μm and the porosity was calculated as 50.9%. SEM and CLSM images showed that the hydrogel was suitable for cell adhesion and growth. The NS-GAM could maintain continuous expression for at least 9 days in vitro, showing long-term gene release and expression effect. Deep second-degree burn wound model was made on the backs of Wistar rats to evaluate the healing effect. The wounds were healed by day 22 in NS-GAM group with the prolonged high expression of VEGF and TGF-β1 protein. A high degree of neovascularization and high expression level of CD34 were observed in NS-GAM group in 21 days. The histological results showed that NS-GAM had good tissue safety and could effectively promote epithelialization and collagen regeneration. These results indicated that the NS-GAM could be applied as a promising local gene delivery system for the repair of deep second-degree burn wounds.
Acellular nerve grafts supplemented with induced pluripotent stem cell-derived exosomes promote peripheral nerve reconstruction and motor function recovery
Authors: Jianfeng Pan, Meng Zhao, Xiangjiao Yi, Jianguo Tao, Shaobo Li, Zengxin Jiang, Biao Cheng, Hengfeng Yuan, Feng Zhang
Journal: Bioactive Materials (2021)

Peripheral nerve injury is a great challenge in clinical work due to the restricted repair gap and weak regrowth ability. Herein, we selected induced pluripotent stem cells (iPSCs) derived exosomes to supplement acellular nerve grafts (ANGs) with the aim of restoring long-distance peripheral nerve defects. Human fibroblasts were reprogrammed into iPSCs through non-integrating transduction of Oct3/4, Sox2, Klf4, and c-Myc. The obtained iPSCs had highly active alkaline phosphatase expression and expressed Oct4, SSEA4, Nanog, Sox2, which also differentiated into all three germ layers in vivo and differentiated into mature peripheral neurons and Schwann cells (SCs) in vitro. After isolation and biological characteristics of iPSCs-derived exosomes, we found that numerous PKH26-labeled exosomes were internalized inside SCs through endocytotic pathway and exhibited a proliferative effect on SCs that were involved in the process of axonal regeneration and remyelination. After that, we prepared ANGs via optimized chemical extracted process to bridge 15 mm long-distance peripheral nerve gaps in rats. Owing to the promotion of iPSCs-derived exosomes, satisfactory regenerative outcomes were achieved including gait behavior analysis, electrophysiological assessment, and morphological analysis of regenerated nerves. Especially, motor function was restored with comparable to those achieved with nerve autografts and there were no significant differences in the fiber diameter and area of reinnervated muscle fibers. Taken together, our combined use of iPSCs-derived exosomes with ANGs demonstrates good promise to restore long-distance peripheral nerve defects, and thus represents a cell-free strategy for future clinical applications.
Glomerular endothelial cell-podocyte stresses and crosstalk in structurally normal kidney transplants
Authors: Rajasree Menon, Edgar A. Otto, Celine C. Berthier, Viji Nair, Evan A. Farkash, Jeffrey B. Hodgin, Yingbao Yang, Jinghui Luo, Kenneth J. Woodside, Haniyeh Zamani, Silas P. Norman, Roger C. Wiggins, Matthias Kretzler, Abhijit S. Naik
Journal: Kidney International (2021)
Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10‐year follow‐up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial
Authors: Robin A.P. Weir, Suzanne Clements, Tracey Steedman, Henry J. Dargie, John J.V. McMurray
Journal: European Journal of Heart Failure (2021)
Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools — Los Angeles County, California, August 16–October 31, 2021
Authors: Kimberly Harris-McCoy, Veronica C. Lee, Cortney Munna, Andrea A. Kim
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

On July 12, 2021, the California Department of Public Health updated COVID-19 school guidance, allowing a Test to Stay (TTS) strategy to increase access to in-person learning* (1). The TTS strategy enabled unvaccinated students, exposed in school to a person infected with SARS-CoV-2 (the virus that causes COVID-19), to remain in school while under quarantine, if both the infected person and the exposed person wore masks correctly and consistently throughout the exposure. To stay in school during the quarantine period, the exposed student must remain asymptomatic, wear a mask at school, and undergo twice weekly testing for SARS-CoV-2. To date, few studies have evaluated the impact of TTS on transmission (2-4). This study evaluated a TTS strategy implemented by Los Angeles County Department of Public Health (LAC DPH). During September 20-October 31, 2021, among 78 school districts, one half permitted TTS; in total, 432 (21%) of 2,067 schools adopted TTS. TTS schools did not experience increases in COVID-19 incidence among students after TTS implementation, and in 20 identified outbreaks in TTS schools,† no tertiary transmission was identified. The ratio of student COVID-19 incidence in TTS districts to that in non-TTS districts was similar before and after TTS adoption (rate ratio = 0.5). Non-TTS schools lost an estimated 92,455 in-person school days during September 20-October 31 while students were in quarantine, compared with no lost days among quarantined students in TTS schools. Non-TTS schools cited resource-related reasons for not adopting TTS; 75% of these schools were in LAC's most disadvantaged neighborhoods. Preliminary data from LAC suggest that a school-based TTS strategy does not increase school transmission of SARS-CoV-2, and might greatly reduce loss of in-person school days; however, TTS might have barriers to implementation and require resources that are not available for some schools. Continued efforts to simplify school quarantine strategies might help to ensure that all students have access to safe in-person education. Although vaccination remains the leading public health recommendation to protect against COVID-19 for persons aged ≥5 years, schools might consider TTS as an option for allowing students with a school exposure who are not fully vaccinated to remain in the classroom as an alternative to home quarantine.
A healthcare system close to collapse in Afghanistan
Authors: Tom Moberly
Journal: BMJ (2021)

A child is treated at Médecins Sans Frontières' inpatient therapeutic feeding centre at Herat Regional Hospital, Afghanistan.The BMJ's annual appeal is this year supporting MSF's work in Afghanistan.The country's health service is now close to collapse, and the World Health Organization predicts that a million Afghan children face starvation this winter.MSF is one of a handful of non-governmental organisations able to maintain high standards of healthcare for the Afghan people.The 2021-22 appeal is being generously supported by the Green Room Charitable Trust.Up to £50 000 (€58 500; $66 000) in funding has been made available to match donations received before 31 January 2022.This means that your support will go even further.MSF's Afghan crisis appeal will support the charity's work in neighbouring countries, as well as in Afghanistan.
Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78
Authors: Fieke W Hoff, Yihua Qiu, Brandon Brown, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, Edward A. Kolb, Todd A. Alonzo, Soheil Meshinchi, Gaye Jenkins, Terzah M. Horton, Steven M. Kornblau
Journal: Blood (2021)
A brain-to-spinal sensorimotor loop for repetitive self-grooming
Authors: Zhiyong Xie, Dapeng Li, Xinyu Cheng, Qing Pei, Huating Gu, Ting Tao, Meizhu Huang, Congping Shang, Dandan Geng, Miao Zhao, Aixue Liu, Chen Zhang, Fan Zhang, Yuanwu Ma, Peng Cao
Journal: Neuron (2021)
A bright future in typhoid vaccines
Authors: None The Lancet Global Health
Journal: The Lancet Global Health (2021)

As we approach the end of the year, we naturally reflect on the progress, stagnations, and regressions that we have seen in 2021. The success of COVID-19 vaccines has dominated global health, but vaccine advances against an older foe have also been robustly, albeit less prominently, underway: those against typhoid fever.
Abstract 12134: Risk of In-Hospital Deterioration for Children With Single Ventricle Physiology
Authors: Henry Foote, Zohaib Shaikh, William Ratliff, Michael Gao, Bradley Hintze, Mark Sendak, Jennifer S Li, Andrew McCrary
Journal: Circulation (2021)

Introduction: Children with single ventricle physiology (SV) are at high risk of in-hospital morbidity and mortality, with much of that increased risk coming in the first year of life. Understanding which children are at the highest risk for clinical deterioration may allow for increased monitoring and earlier escalation of care, with associated decreased mortality. Methods: We conducted a retrospective chart review of all admissions to the pediatric cardiology non-ICU inpatient service from 2014 - 2018 for children &lt; 18 years old. Clinical deterioration was defined as an unplanned transfer to the ICU or inpatient mortality. Children with SV were selected by diagnosis codes. Results: From the entire cohort of 1612 pediatric cardiology admissions (56 % male, 25% SV), 288 admissions had a deterioration event including 26 deaths. Infants less than one year with SV (n = 197 admissions) were significantly more likely to have a deterioration event (107 events over 62 admissions with an event) than the overall pediatric cardiology cohort (OR 2.11, 95% CI 1.52-2.93). Among infants with SV, those with a deterioration event were significantly younger (median 1.7 v 4.3 months, p &lt; 0.001). Further, at baseline they had significantly lower oxygen saturation (84% v 87%, p &lt; 0.01), lower systolic blood pressure (85mmHg v 90mmHg, p&lt; 0.02), higher respiration rate (48 v 44, p &lt; 0.01), and higher hematocrit (44.0 v 40.2, p &lt; 0.005) compared to those who remained stable. Mean Pediatric Early Warning Scores (PEWS) were significantly higher for infants with SV who had a deterioration event (1.4 v 0.9, p &lt; 0.001) and PEWS scores significantly increased in the 48 hours prior to an event (p &lt; 0.001). Of the 104 non-death events, 61 required an increase in oxygen support and 51 required a fluid bolus prior to the event (p &lt; 0.001). Conclusions: Infants with SV are at high risk for clinical deterioration. There are baseline differences in vital signs and lab work between those that remain stable and those that have a deterioration event. PEWS scores and oxygen and fluid treatment significantly increase prior to deterioration events. Leveraging data from the Electronic Medical Record to identify the highest risk patients may allow for earlier detection and intervention to prevent clinical deterioration.
Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study
Authors: Jingwen Ai, Jitao Wang, Dengxiang Liu, Huiling Xiang, Ying Guo, Jiaojian Lv, Qiran Zhang, Jinlong Li, Xiaochong Zhang, Qianqian Li, Jing Liang, Xiaoqing Guo, Yinong Feng, Luxiang Liu, Xuying Zhang, Wei Qin, Xiaodong Wang, Wei Rao, Qun Zhang, Qiuju Tian, Yanliang Zhang, Faren Xie, Shujun Jiang, Yan Yan, Yuanwang Qiu, Hangyuan Wu, Zhiyun Hou, Nina Zhang, Aiguo Zhang, Jiansong Ji, Jie Yang, Jiansheng Huang, Zhongwei Zhao, Ye Gu, Li Bian, Zhen Zhang, Shengqiang Zou, Hailei Ji, Guohong Ge, Xiufang Du, Aifang Hou, Ying Zhu, Qingwei Cong, Juan Xu, Hongmei Zu, Yun Wang, Zhaolan Yan, Xiaosong Yan, Yangzhen BianBa, Qu Ci, Liting Zhang, Shiying Yang, Xiaoqin Gao, Li Zhong, Song He, Chuan Liu, Yifei Huang, Yanna Liu, Dan Xu, Qingliang Zhu, Xinxin Xu, Muhan Lv, Wenhong Zhang, Xiaolong Qi
Journal: Clinical Gastroenterology and Hepatology (2021)
Abstract 9115: Determining Optimal Hemoglobin Transfusion Threshold for Patients With Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis
Authors: Nitish Sood, Arnav Goyal, Dayton Grogan, Vamsi Reddy
Journal: Circulation (2021)

Introduction: Multiple randomized controlled trials have found that a conservative approach to transfusing critically ill patients reduces mortality, with current guidelines recommending a hemoglobin (HgB) transfusion threshold of 7 g/dL. However, little work has examined whether this transfusion threshold reduces mortality in patients with severe traumatic brain injury (TBI). Here, we present a systematic review and meta-analysis of the literature. Methods: A systematic search was conducted on PubMed, Ovid, and Web of Science. Full-text articles were eligible if patients with TBI, defined as Glasgow Coma Score &lt;= 8, were divided into multiple groups with varying hemoglobin transfusion thresholds and reported any outcome of interest including mortality, number of packed red blood cell (PRBC) units transfused, length of stay in ICU, and length of stay in the hospital. Eight studies were eligible (n = 3663). We compared mortality rates at HgB transfusion thresholds of &lt; 7 g/dL, &lt; 8 g/dL, &lt; 9 g/dL, and &lt; 10 g/dL. Results: We found that traditionally ‘conservative’ approaches to anemia management (HgB &lt; 7 g/dL, &lt; 8 g/dL, and &lt; 9 g/dL) were associated with decreased mortality when compared to traditionally ‘liberal’ approaches (HgB &lt; 10 g/dL), with p &lt; 0.05. Results were robust across both frequentist and Bayesian analysis. As a surrogate for cost of care and use of hospital resources, the total number of PRBC units transfused to patients, length of stay in ICU, and length of stay in hospital were analyzed. We found that using a transfusion threshold &lt; 7 g/dL compared to &lt; 10 g/dL substantially decreased the number of PRBC units transfused. In three of five cohorts, the cohort with the lower HgB transfusion threshold or no transfusion had a significantly shorter length of stay in the ICU and in the hospital. The remaining two cohorts found no significant difference in the length of stays in ICU or hospital. Conclusion: This study demonstrates that conservative approaches to transfusions ( &lt; 7 g/dL, &lt; 8 g/dL, or &lt; 9 g/dL) significantly reduce mortality and the number of PRBC units transfused when compared to more liberal approaches ( &lt; 10 g/dL). Current evidence is unclear on the benefits of conservative approaches in reduction of ICU or hospital length of stay.
Persistent Post COVID-19 Symptoms and Functional Status after 12-14 weeks of recovery, Tamil Nadu, India, 2021
Authors: Polani Rubeshkumar, Alby John, Manish Narnaware, Jagadeesan M, Fermi Vidya, Rajeshkumar Gurunathan, Parasuraman Ganeshkumar, Gagandeep Singh Bedi, Prabhdeep Kaur
Journal: Journal of Infection (2021)
PSMB4 and PSMD4 Are Correlated with 1q21 Amplification in CD138 + Plasma Cells: New Potential Druggable Targets in Myeloma Patients
Authors: Jessica Burroughs-Garcia, Paola Storti, Luca Agnelli, Denise Toscani, Valentina Marchica, Gabriella Sammarelli, Giannalisa Todaro, Vincenzo Raimondi, Valentina Franceschi, Naomi Soressi, Anna Benedetta Dalla Palma, Laura Notarfranchi, Gaetano Donofrio, Nicola Giuliani
Journal: Blood (2021)
FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study
Authors: Francois-Xavier Mahon, Johan Richter, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Medina de Almeida, Jiri Mayer, Henrik Hjorth-Hansen, Jeroen Janssen, Satu Mustjoki, Joaquín Martínez-López, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Stephanie Dulucq, Katerina Machova, Franck E. Nicolini, Wolf-Karsten Hofmann, Joelle Guilhot, Susanne Saussele, Markus Pfirrmann
Journal: Blood (2021)
Treatment of Severe Nail Lichen Planus With Baricitinib
Authors: Jöri Pünchera, Emmanuel Laffitte
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Authors: Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett
Journal: Journal of Clinical Oncology (2021)

Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).This first-in-human trial (ClinicalTrials.gov identifier: NCT02500407) evaluated the safety and tolerability and efficacy of mosunetuzumab in patients with R/R B-NHL and established the recommended phase II dose. Data from dose escalation are presented. Single-agent mosunetuzumab was administered intravenously in 3-week cycles, at full dose in cycle 1 day 1 (group A) or with ascending (step-up) doses during cycle 1 on days 1, 8, and 15 (group B), for eight or 17 cycles on the basis of tumor response.Two hundred thirty patients were enrolled. Doses up to 2.8 mg and 60 mg were assessed in groups A and B, respectively; maximum tolerated dose was not exceeded. In group B (n = 197), common adverse events (≥ 20% of patients) were neutropenia (28.4%), cytokine release syndrome (27.4%), hypophosphatemia (23.4%), fatigue (22.8%), and diarrhea (21.8%). Cytokine release syndrome was mostly low-grade (grade ≥ 3: 1.0%) and mainly confined to cycle 1. Across the doses investigated (group B), best overall response rates were 34.9% and 66.2% in patients with aggressive and indolent B-NHL, respectively, and complete response rates were 19.4% and 48.5%. Among patients with a complete response, the median duration of response was 22.8 months (95% CI, 7.6 to not estimable) and 20.4 (95% CI, 16 to not estimable) in patients with aggressive and indolent B-NHL, respectively.Mosunetuzumab, administered with step-up dosing, has a manageable safety profile and induces durable complete responses in R/R B-NHL. The expansion stage of the study is ongoing at the dose level of 1/2/60/60/30 mg selected for further study.
Safeguarding people living in vulnerable conditions in the COVID-19 era through universal health coverage and social protection
Authors: Gabriela Cuevas Barron, George Laryea-Adjei, Vaira Vike-Freiberga, Ibrahim Abubakar, Henia Dakkak, Delanjathan Devakumar, Anders Johnsson, Selma Karabey, Ronald Labonté, Helena Legido-Quigley, Peter Lloyd-Sherlock, Isaac Iyinoluwa Olufadewa, Harold Calvin Ray, Irwin Redlener, Karen Redlener, Ismail Serageldin, Nisia Trindade Lima, Virgilio Viana, Katherine Zappone, Uyen Kim Huynh, Nicole Schlosberg, Hanlu Sun, Ozge Karadag
Journal: The Lancet Public Health (2021)

The COVID-19 pandemic is unprecedented. The pandemic not only induced a public health crisis, but has led to severe economic, social, and educational crises. Across economies and societies, the distributional consequences of the pandemic have been uneven. Among groups living in vulnerable conditions, the pandemic substantially magnified the inequality gaps, with possible negative implications for these individuals' long-term physical, socioeconomic, and mental wellbeing. This Viewpoint proposes priority, programmatic, and policy recommendations that governments, resource partners, and relevant stakeholders should consider in formulating medium-term to long-term strategies for preventing the spread of COVID-19, addressing the virus's impacts, and decreasing health inequalities. The world is at a never more crucial moment, requiring collaboration and cooperation from all sectors to mitigate the inequality gaps and improve people's health and wellbeing with universal health coverage and social protection, in addition to implementation of the health in all policies approach.
VITT after ChAdOx1 nCoV-19 Vaccination
Authors: Charlotte Bradbury, Quentin Hill, Rosemary Greenwood
Journal: New England Journal of Medicine (2021)

stages of the trial, including funding acquisition and publication.Finally, we clearly state in the article that mycophenolate increases the risk of miscarriage and birth defects, and stringent contraceptive measures were required during the trial.In addition, we have been very careful to avoid the conclusion of recommending mycophenolate mofetil as a routine first-line option and have called for further research to clarify the role of this drug in treatment pathways.In response to van Dijk and Schutgens: we selected the generic quality-of-life tools for their validity, reliability, and responsiveness in adult patients with ITP. 3 We chose to use the area under the curve (as is used in health economic analysis) to assess patients' quality of life during the entire follow-up period rather than at an individual time point.We acknowledge that the differences in quality-of-life scores could be chance findings after adjustment for multiple testing, and we agree that the clinical importance of this difference has not been proved and that combination therapy may be justified in some circumstances.